We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Immupharma Plc (IMM) Ordinary 1p

Sell:2.52p Buy:2.74p 0 Change: 0.11p (4.06%)
Market closed |  Prices as at close on 23 May 2025 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:2.52p
Buy:2.74p
Change: 0.11p (4.06%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 23 May 2025 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:2.52p
Buy:2.74p
Change: 0.11p (4.06%)
Market closed |  Prices as at close on 23 May 2025 Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Share news, reports & tips

  • ImmuPharma can't explain near-400% stock jump

    28 January 2025 13:09

    (Sharecast News) - Specialist drug discovery and development outfit ImmuPharma has said that it can't pinpoint a reason behind its share price more than quadrapling over the past month.

  • ImmuPharma progresses P140 clinical programme with FDA

    12 April 2023 14:13

    (Sharecast News) - Drug discovery and development company ImmuPharma announced positive progress in its late-stage P140 clinical programme on Tuesday, for patients with chronic idiopathic demyelinating...

  • ImmuPharma upbeat after meeting with US partner Avion

    11 November 2022 13:04

    (Sharecast News) - Drug discovery and development specialist ImmuPharma updated the market on a recent meeting in Atlanta with its United States partner Avion Pharmaceuticals on Friday, for strategic...

  • ImmuPharma's US partner receives FDA response on Lupuzor

    14 September 2022 13:51

    (Sharecast News) - Specialist drug discovery and development company ImmuPharma announced on Wednesday that its US partner for 'Lupuzor', Avion Pharmaceuticals, has received a written response from...

Company announcements Announcements


Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.

© Digital Look Ltd 1998-2025. All rights reserved.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.